Literature DB >> 19390551

Immunotherapy: Vaccine trials in melanoma -- time for reflection.

Alexander M M Eggermont1.   

Abstract

The disappointing results of the large, randomized, controlled trials showing no benefit of vaccines in patients with advanced and metastatic melanoma call for a reassessment of the development of therapeutic vaccines and the importance of better immune monitoring methodology, such as adoptive T-cell therapy with lymphodepletion.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19390551     DOI： 10.1038/nrclinonc.2009.42

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  11 in total

1.  Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

Authors:  D Schadendorf; S Ugurel; B Schuler-Thurner; F O Nestle; A Enk; E-B Bröcker; S Grabbe; W Rittgen; L Edler; A Sucker; C Zimpfer-Rechner; T Berger; J Kamarashev; G Burg; H Jonuleit; A Tüttenberg; J C Becker; P Keikavoussi; E Kämpgen; G Schuler
Journal:  Ann Oncol       Date:  2006-01-17       Impact factor: 32.976

2.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

Authors:  Mark E Dudley; James C Yang; Richard Sherry; Marybeth S Hughes; Richard Royal; Udai Kammula; Paul F Robbins; JianPing Huang; Deborah E Citrin; Susan F Leitman; John Wunderlich; Nicholas P Restifo; Armen Thomasian; Stephanie G Downey; Franz O Smith; Jacob Klapper; Kathleen Morton; Carolyn Laurencot; Donald E White; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

3.  Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.

Authors:  Ajay V Maker; Peter Attia; Steven A Rosenberg
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

4.  High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.

Authors:  J M Kirkwood; J G Ibrahim; J A Sosman; V K Sondak; S S Agarwala; M S Ernstoff; U Rao
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

Review 5.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

Authors:  Steven A Rosenberg; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

6.  Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.

Authors:  Franz O Smith; Stephanie G Downey; Jacob A Klapper; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Nicholas P Restifo; Catherine L Levy; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

7.  Cancer immunotherapy: moving beyond current vaccines.

Authors:  Steven A Rosenberg; James C Yang; Nicholas P Restifo
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

8.  Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.

Authors:  Jeffrey A Sosman; Carole Carrillo; Walter J Urba; Lawrence Flaherty; Michael B Atkins; Joseph I Clark; Janet Dutcher; Kim A Margolin; James Mier; Jarod Gollob; John M Kirkwood; David J Panka; Nancy A Crosby; Kevin O'Boyle; Bonnie LaFleur; Marc S Ernstoff
Journal:  J Clin Oncol       Date:  2008-05-10       Impact factor: 44.544

Review 9.  Randomized adjuvant therapy trials in melanoma: surgical and systemic.

Authors:  Alexander M M Eggermont; Martin Gore
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

10.  Alloimmune cells consume interleukin-2 and competitively inhibit the anti-tumour effects of interleukin-2.

Authors:  A M Eggermont; E P Steller; W Matthews; P H Sugarbaker
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640
View more
  10 in total

1.  Advanced malignant melanoma: immunologic and multimodal therapeutic strategies.

Authors:  Niels Halama; Inka Zoernig; Dirk Jaeger
Journal:  J Oncol       Date:  2010-03-09       Impact factor: 4.375

2.  Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.

Authors:  An M T Van Nuffel; Daphné Benteyn; Sofie Wilgenhof; Lauranne Pierret; Jurgen Corthals; Carlo Heirman; Pierre van der Bruggen; Pierre G Coulie; Bart Neyns; Kris Thielemans; Aude Bonehill
Journal:  Mol Ther       Date:  2012-02-28       Impact factor: 11.454

3.  Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma.

Authors:  Ricardo J Gonzalez; Ragini Kudchadkar; Nikhil G Rao; Vernon K Sondak
Journal:  Ochsner J       Date:  2010

Review 4.  Update on vaccines for high-risk melanoma.

Authors:  Sarah A Weiss; Sunandana Chandra; Anna C Pavlick
Journal:  Curr Treat Options Oncol       Date:  2014-06

5.  Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.

Authors:  Simone M Goldinger; Reinhard Dummer; Petra Baumgaertner; Daniela Mihic-Probst; Katrin Schwarz; Anya Hammann-Haenni; Joerg Willers; Christine Geldhof; John O Prior; Thomas M Kündig; Olivier Michielin; Martin F Bachmann; Daniel E Speiser
Journal:  Eur J Immunol       Date:  2012-08-28       Impact factor: 5.532

6.  High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes.

Authors:  Ludovic Martinet; Sophie Le Guellec; Thomas Filleron; Laurence Lamant; Nicolas Meyer; Philippe Rochaix; Ignacio Garrido; Jean-Philippe Girard
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

7.  Immunotherapy earns its spot in the ranks of cancer therapy.

Authors:  Drew Pardoll; Charles Drake
Journal:  J Exp Med       Date:  2012-02-13       Impact factor: 14.307

8.  A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.

Authors:  Lisa M Ebert; Sarah E MacRaild; Damien Zanker; Ian D Davis; Jonathan Cebon; Weisan Chen
Journal:  PLoS One       Date:  2012-10-26       Impact factor: 3.240

9.  Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.

Authors:  Fernando Aranda; Erika Vacchelli; Alexander Eggermont; Jerome Galon; Wolf Hervé Fridman; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-02-01       Impact factor: 8.110

10.  MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial.

Authors:  Emanuela Romano; Olivier Michielin; Verena Voelter; Julien Laurent; Hélène Bichat; Athina Stravodimou; Pedro Romero; Daniel E Speiser; Frédéric Triebel; Serge Leyvraz; Alexandre Harari
Journal:  J Transl Med       Date:  2014-04-12       Impact factor: 5.531
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.